NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDBaricitinib Olumiant®
(2mg and 4mg f/c tablets) 		Skin, Drugs affecting the immune response, 13.05.03
REDBaricitinib Olumiant® ( 2mg and 4 mg tablets) Infections, Antiviral drugs, 05.03
REDBaricitinib 2mg, 4mg Olumiant®
(Tablets) 		Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
REDBaricitinib 2mg, 4mg Olumiant®
(Tablets) 		Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Baricitinib Baricitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Baricitinib Baricitinib Skin, Skin, Inflammatory Skin Conditions, Immunosuppressants JAK Inhibitors
Baricitinib Baricitinib Skin, Skin, Scalp And Hair Conditions, Immunosuppressants JAK Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
Medicine Request Form - Baricitinib
Medicine Request Form (Bedford) - Baricitinib
Medicine Request Form (Luton) - Baricitinib
MHRA Drug Safety Update: Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors (August 2020)
MHRA Drug Safety Update: Baricitinib (Olumiant¥): increased risk of diverticulitis, particularly in patients with risk factors (August 2020)
MHRA Drug Safety Update: Baricitinib (Olumiant¥): risk of venous thromboembolism (March 2020)
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
NICE TA926: Baricitinib for treating severe alopecia areata (NOT RECOMMENDED)
NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (TERMINATED APPRAISAL)